Corporate ActionJul 15, 2026, 04:18 PM
Biodexa Registers 2.55M ADSs for Resale by Shareholders
AI Summary
Biodexa Pharmaceuticals Plc filed an F-1 registration statement for the resale of 2,555,095 American Depositary Shares (ADSs) by selling shareholders. These ADSs represent 1.28 trillion Ordinary Shares and are issuable upon the exercise of various warrants (Pre-Funded, Series M, N, and O) issued in recent capital raising transactions. The company will not receive proceeds from the resale of ADSs, but may receive proceeds from warrant exercises.
Key Highlights
- Registration of 2,555,095 American Depositary Shares (ADSs) for resale by selling shareholders.
- ADSs represent 1,277,547,500,000 Ordinary Shares of Biodexa Pharmaceuticals Plc.
- Securities originate from Pre-Funded, Series M, Series N, and Series O Warrants.
- Registered Direct Offering on July 1, 2026, generated approximately $0.8 million gross proceeds.
- Warrant Inducement transaction on July 1, 2026, generated approximately $1.7 million gross proceeds.
- July 2026 Private Placement generated approximately $1.0 million gross proceeds.
- Each Depositary Share represents 500,000 Ordinary Shares.
- Company will not receive proceeds from the resale of ADSs, but may from warrant exercises.
Price Impact
More from BDRX